Specifications

Product Data
Applications	IHC, WB
Recommended Dilution	WB: 500-2000 WB positive control: Human fetal brain tissue IHC: 25-100 Positive control: Human colon cancer Predicted cell location: Cytoplasm
Reactivities	Human
Host	Rabbit
Isotype	IgG
Clonality	Polyclonal
Immunogen	Full length fusion protein
Formulation	PBS pH7.3, 0.05% NaN3, 50% glycerol
Concentration	lot specific
Purification	Antigen affinity purification
Conjugation	Unconjugated
Storage	Store at -20°C as received.
Stability	Stable for 12 months from date of receipt.
Gene Name	von Hippel-Lindau tumor suppressor
Database Link	NP_000542 Entrez Gene 7428 Human UniProt ID P40337
Background	Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B; elongin C; and cullin-2; and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF); which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
Synonyms	HRCA1; pVHL; RCA1; VHL1
Reference Data
Protein Families	Druggable Genome, Transcription Factors
Protein Pathways	Pathways in cancer, Renal cell carcinoma, Ubiquitin mediated proteolysis